The history and future of treatment of hypothyroidism

Annals of Internal Medicine

Volumn 164, Issue 1, 2016, Pages 50-56

  McAninch, Elizabeth A ^a   Bianco, Antonio C ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE; LEVOTHYROXINE; LIOTHYRONINE; THYROGLOBULIN; THYROID EXTRACT; THYROTROPIN; THYROXINE; BIOLOGICAL MARKER; PLASMA PROTEIN; PROTEIN BINDING; THYROID HORMONE;

ARTICLE; BASAL METABOLIC RATE; CLINICAL PRACTICE; HORMONAL THERAPY; HUMAN; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BOUND IODINE; RADIOIMMUNOASSAY; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL; BLOOD; HISTORY; HORMONE SUBSTITUTION; METABOLISM;

BASAL METABOLISM; BIOMARKERS; BLOOD PROTEINS; HISTORY, 20TH CENTURY; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOTHYROIDISM; IODINE; PROTEIN BINDING; THYROID HORMONES;

EID: 84953266739     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-1799     Document Type: Article

References (81)

1. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24:1670-751. [PMID: 25266247].
2. Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP. 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J. 2012;1:55-71. [PMID: 24782999].
3. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on 'adequate' doses of L-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002;57:577-85. [PMID: 12390330].
4. Gullo D, Latina A, Frasca F, Le Moli R, Pellegriti G, Vigneri R. Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. PLoS One. 2011;6:e22552. [PMID: 21829633].
5. Abdalla SM, Bianco AC. Defending plasma T3 is a biological priority. Clin Endocrinol (Oxf). 2014;81:633-41. [PMID: 25040645].
6. Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ Jr. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med. 1999;340:424-9. [PMID: 9971866].
7. Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley AT, Frayling TM, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009;94:1623-9. [PMID: 19190113].
8. Escobar-Morreale HF, del Rey FE, Obregón MJ, de Escobar GM. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology. 1996;137:2490-502. [PMID: 8641203].
9. Werneck de Castro JP, Fonseca TL, Ueta CB, McAninch EA, Abdalla S, Wittmann G, et al. Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine. J Clin Invest. 2015;125:769-81. [PMID: 25555216].
10. McAninch EA, Jo S, Preite NZ, Farkas E, Mohácsik P, Fekete C, et al. Prevalent polymorphism in thyroid hormone-activating enzyme leaves a genetic fingerprint that underlies associated clinical syndromes. J Clin Endocrinol Metab. 2015;100:920-33. [PMID: 25569702].
11. Lindholm J, Laurberg P. Hypothyroidism and thyroid substitution: historical aspects. J Thyroid Res. 2011;2011:809341. [PMID: 21760981].
12. Lundie RA. The treatment of myxoedema. Edinburgh Medical Journal. 1893;38:996-1005.
13. Kocher A. The treatment of hypothyroidism by thyroid transplantation. Br Med J. 1923;2:560-1. [PMID: 20771297].
14. Bettencourt R, Serrano J. Un cas de myxoedème traitépar la greffe hypodermique du corps thyroïde d'un mouton. La Semaine Médicale. 1890;10:294.
15. Ord WM, White E. Clinical remarks on certain changes observed in the urine in myxoedema after the administration of glycerine extract of thyroid gland. Br Med J. 1893;2:217.
16. Mackenzie HW. A case of myxoedema treated with great benefit by feeding with fresh thyroid glands. Br Med J. 1892;2:940-1.
17. Dawson R. Correspondence. Montreal Medical Journal. 1893;22: 437-9.
18. Ma R, Latif R, Davies TF. Human embryonic stem cells form functional thyroid follicles. Thyroid. 2015;25:455-61. [PMID: 25585054].
19. Magnus-Levy A. Energy metabolism in health and disease. J Hist Med Allied Sci. 1947;2:307-20. [PMID: 20266805].
20. Stanbury JB. A Constant Ferment. Ipswich, MA: Ipswich Pr; 1991.
21. Palmer WW. Metabolism in hyperthyroidism and hypothyroidism. Bull N Y Acad Med. 1934;10:52-64. [PMID: 19311910].
22. Chesky VE. The Hospital Management of Goiter Patients. Diseases of the Thyroid Gland. 2nd ed. St. Louis: CV Mosby; 1929: 209-29.
23. Chalmers JR, Dickson GT, Elks J, Hems BA. The synthesis of thyroxine and related substances. Part V. A synthesis of L-thyroxine from L-tyrosine. Journal of the Chemical Society. 1949:3424-38.
24. Hart FD, Maclagan NF. Synthetic thyroxine in the treatment of myxoedema. J Endocrinol. 1950;6:xxxiv. [PMID: 14774506].
25. Williams RH. Relation of obesity to the function of the thyroid gland, especially as indicated by the protein-bound iodine concentration in the plasma. J Clin Endocrinol Metab. 1948;8:257-61. [PMID: 18912537].
26. Braverman LE, Ingbar SH. Anomalous effects of certain preparations of desiccated thyroid on serum protein-bound iodine. N Engl J Med. 1964;270:439-42. [PMID: 14163222].
27. Ingbar SH, Woeber KA. Thyroid hormone deficiency. In: Williams RH, ed. Textbook of Endocrinology. 4th ed. Philadelphia: WB Saunders; 1968:232-58.
28. Cobb WE, Jackson IM. Drug therapy reviews: management of hypothyroidism. Am J Hosp Pharm. 1978;35:51-8. [PMID: 341699].
29. Thompson WO, McLellan LL, Thompson PK, Dickie LF. The rates of utilization of thyroxine and of desiccated thyroid in man: the relation between the iodine in desiccated thyroid and in thyroxine. J Clin Invest. 1933;12:235-46. [PMID: 16694117].
30. Gross J, Pitt-Rivers R, Trotter WR. Effect of 3:5:3'-Ltriiodothyronine in myxoedema. Lancet. 1952;1:1044-5. [PMID: 14928556].
31. Asper SP Jr, Selenkow HA, Plamondon CA. A comparison of the metabolic activities of 3,5,3-L-triiodothyronine and Lthyroxine in myxedema. Bull Johns Hopkins Hosp. 1953;93:164-98. [PMID: 13094265].
32. McGavack TH, Reckendorf HK. Therapeutic activity of desiccated thyroid substance, sodium L-thyroxine and D,L-triiodothyronine; a comparative study. Am J Med. 1956;20:774-7. [PMID: 13313575].
33. Williams RH. The thyroid. In: Williams RH, ed. Textbook of Endocrinology. 2nd ed. Philadelphia: WB Saunders; 1955:99-220.
34. Frawley TF, McClintock JC, Beebe RT, Marthy GL. Metabolic and therapeutic effects of triiodothyronine. J Am Med Assoc. 1956;160: 646-52. [PMID: 13286110].
35. Smith RN, Taylor SA, Massey JC. Controlled clinical trial of combined triiodothyronine and thyroxine in the treatment of hypothyroidism. Br Med J. 1970;4:145-8. [PMID: 4097650].
36. Werner SC. Treatment; myxedema coma; nonspecific uses of thyroid medication. In: Werner SC, Ingbar SH, eds. The Thyroid: A Fundamental and Clinical Text. 3rd ed. New York: Harper & Row; 1971:832-8.
37. Werner SC. Pharmacology; treatment. In: Werner SC, ed. The Thyroid: A Fundamental and Clinical Text. 2nd ed. New York: Harper & Row; 1962:817-25.
38. Kaufman SC, Gross TP, Kennedy DL. Thyroid hormone use: trends in the United States from 1960 through 1988. Thyroid. 1991; 1:285-91. [PMID: 1841728].
39. Mangieri CN, Lund MH. Potency of United States Pharmacopeia dessicated thyroid tablets as determined by the antigoitrogenic assay in rats. J Clin Endocrinol Metab. 1970;30:102-4. [PMID: 5409525].
40. DeGroot LJ, Larsen PR, Hennemann G. Treatment of the patient with primary hypothyroidism. In: The Thyroid and Its Diseases. 6th ed. London: Churchill Livingstone; 1996:351-6.
41. Lavietes PH, Epstein FH. Thyroid therapy of myxedema: a comparison of various agents with a note on the composition of thyroid secretion in man. Ann Intern Med. 1964;60:79-87. [PMID: 14104859].
42. Braverman LE, Ingbar SH, Sterling K. Conversion of thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects. J Clin Invest. 1970;49:855-64. [PMID: 4986007].
43. Utiger RD. Thyrotrophin radioimmunoassay: another test of thyroid function. Ann Intern Med. 1971;74:627-9. [PMID: 5551168].
44. Hershman JM, Pittman JA Jr. Utility of the radioimmunoassay of serum thyrotrophin in man. Ann Intern Med. 1971;74:481-90. [PMID: 4994544].
45. Cotton GE, Gorman CA, Mayberry WE. Suppression of thyrotropin (h-TSH) in serums of patients with myxedema of varying etiology treated with thyroid hormones. N Engl J Med. 1971;285:529-33. [PMID: 5109216].
46. Evered D, Young ET, Ormston BJ, Menzies R, Smith PA, Hall R. Treatment of hypothyroidism: a reappraisal of thyroxine therapy. Br Med J. 1973;3:131-4. [PMID: 4720761].
47. Taylor PN, Iqbal A, Minassian C, Sayers A, Draman MS, Greenwood R, et al. Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern Med. 2014;174:32-9. [PMID: 24100714].
48. Surks MI, Schadlow AR, Oppenheimer JH. A new radioimmunoassay for plasma L-triiodothyronine: measurements in thyroid disease and in patients maintained on hormonal replacement. J Clin Invest. 1972;51:3104-13. [PMID: 4539287].
49. Larsen PR, Dockalova J, Sipula D, Wu FM. Immunoassay of thyroxine in unextracted human serum. J Clin Endocrinol Metab. 1973; 37:177-82. [PMID: 4198255].
50. Jackson IM, Cobb WE. Why does anyone still use desiccated thyroid USP? Am J Med. 1978;64:284-8. [PMID: 629277].
51. Surks MI, Schadlow AR, Stock JM, Oppenheimer JH. Determination of iodothyronine absorption and conversion of L-thyroxine (T4) to L-triiodothyronine (T3) using turnover rate techniques. J Clin Invest. 1973;52:805-11. [PMID: 4693647].
52. Woeber KA, Braverman LE. The thyroid. In: Ingbar SH, ed. Contemporary Endocrinology. New York: Plenum; 1979:77-117.
53. Gorman CA, Jiang NS, Ellefson RD, Elveback LR. Comparative effectiveness of dextrothyroxine and levothyroxine in correcting hypothyroidism and lowering blood lipid levels in hypothyroid patients. J Clin Endocrinol Metab. 1979;49:1-7. [PMID: 447807].
54. Duntas LH. Thyroid disease and lipids. Thyroid. 2002;12:287-93. [PMID: 12034052].
55. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421. [PMID: 12485966].
56. Tanis BC, Westendorp GJ, Smelt HM. Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies. Clin Endocrinol (Oxf). 1996;44:643-9. [PMID: 8759176].
57. Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012; 379:1142-54. [PMID: 22273398].
58. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-38. [PMID: 14722150].
59. Ingbar SH, Woeber KA. Thyroid hormone deficiency. In: Williams RH, ed. Textbook of Endocrinology. 5th ed. Philadelphia: WB Saunders; 1974:191-212.
60. Hoang TD, Olsen CH, Mai VQ, Clyde PW, Shakir MK. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab. 2013;98:1982-90. [PMID: 23539727].
61. Kazerouni F, Amirrasouli H. Performance characteristics of three automated immunoassays for thyroid hormones. Caspian J Intern Med. 2012;3:400-104. [PMID: 24358433].
62. Hoffenberg R. Primary hypothyroidism. In: Ingbar SH, Braverman LE, eds. Werner's The Thyroid: A Fundamental and Clinical Text. 5th ed. Philadelphia: JB Lippincott; 1978:1255-66.
63. Werner SC. Treatment. In: Werner SC, Ingbar SH, eds. The Thyroid: A Fundamental and Clinical Text. 4th ed. Baltimore: Harper & Row; 1978:965-70.
64. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160:526-34. [PMID: 10695693].
65. Carr D, McLeod DT, Parry G, Thornes HM. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol (Oxf). 1988;28:325-33. [PMID: 3139338].
66. Walsh JP, Ward LC, Burke V, Bhagat CI, Shiels L, Henley D, et al. Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial. J Clin Endocrinol Metab. 2006;91:2624-30. [PMID: 16670161].
67. Roberts N. Psychological problems in thyroid disease. British Thyroid Foundation Newsletter. 1996:3.
68. Saravanan P, Visser TJ, Dayan CM. Psychological well-being correlates with free thyroxine but not free 3,5,3'-triiodothyronine levels in patients on thyroid hormone replacement. J Clin Endocrinol Metab. 2006;91:3389-93. [PMID: 16804044].
69. Skinner GR, Thomas R, Taylor M, Sellarajah M, Bolt S, Krett S, et al. Thyroxine should be tried in clinically hypothyroid but biochemically euthyroid patients [Letter]. BMJ. 1997;314:1764. [PMID: 9202524].
70. Wiersinga WM. Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism. Nat Rev Endocrinol. 2014;10:164-74. [PMID: 24419358].
71. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA. 1995;273:808-12. [PMID: 7532241].
72. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al; American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012;22:1200-35. [PMID: 22954017].
73. Peeters RP, van Toor H, Klootwijk W, de Rijke YB, Kuiper GG, Uitterlinden AG, et al. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab. 2003;88:2880-8. [PMID: 12788902].
74. McAninch EA, Jo S, Preite NZ, Farkas E, Mohácsik P, Fekete C, et al. Prevalent polymorphism in thyroid hormone-activating enzyme leaves a genetic fingerprint that underlies associated clinical syndromes. J Clin Endocrinol Metab. 2015;100:920-33. [PMID: 25569702].
75. Bianco AC, Casula S. Thyroid hormone replacement therapy: three 'simple' questions, complex answers. Eur Thyroid J. 2012;1:88-98. [PMID: 24783002].
76. Means JH. Myxedema. In: The Thyroid and Its Diseases. 2nd ed. Philadelphia: JB Lippincott; 1948:241-73.
77. Soffer LJ. Hypothyroidism: cretinism, juvenile and adult myxedema (Gulls' disease). In: Diseases of the Endocrine Glands. 2nd ed. Philadelphia: Lea & Febiger; 1956:829-68.
78. Williams RH, Bakke JL. General consideration of the treatment of thyroid disease. In: Williams RH, ed. Textbook of Endocrinology. 3rd ed. Philadelphia: WB Saunders; 1962:133-5.
79. Pittman JA. Hypothyroidism. In: Diagnosis and Treatment of Thyroid Diseases. Philadelphia: FA Davis; 1963:56-78.
80. Hoffenberg R. Primary hypothyroidism. In: Ingbar SH, Braverman LE, eds. Werner's The Thyroid: A Fundamental and Clinical Text. 5th ed. Philadelphia: JB Lippincott; 1986:1255-65.
81. Volpe R. Hypothyroidism. In: Burrow GN, Oppenheimer JH, Volpe R, eds. Thyroid Function & Disease. Philadelphia: WB Saunders; 1989:274-91.